Kenza Health Hub logoGet Started
1 May 2026Oral drugsSource update: April 2024

Levodopa/Carbidopa oral

Levodopa and carbidopa guidance for Parkinson's disease and non-antipsychotic extrapyramidal disorders, with gradual titration and psychiatric precautions.

Prescription under medical supervision
This guide page is for structured reference only and does not replace a clinician, pharmacist, or emergency review. Dose choice, route choice, interactions, and safety decisions still need professional judgment.

Therapeutic action

Antiparkinson drug.

Indications

Parkinson's disease and extrapyramidal disorders except those induced by antipsychotics.

Forms and strengths

  • 100 mg levodopa + 10 mg carbidopa tablet.
  • 250 mg levodopa + 25 mg carbidopa tablet.

Dose

Doses are expressed as levodopa.

  • Adult: initial dose 50 to 125 mg 3 times daily, immediately after meals.
  • Increase by 50 to 125 mg every day or every 2 days until the optimal dose for the individual patient is reached.
  • Maintenance dose usually: 250 to 500 mg 3 times daily, immediately after meals, maximum 2 g daily.
  • Reduce dosage in older patients.

Duration

According to clinical response.

Contra-indications, adverse effects, precautions

  • Do not administer in severe psychosis, confusion, closed-angle glaucoma, recent myocardial infarction, or malignant melanoma.
  • Early in treatment when dose is not adjusted, may cause anorexia, vomiting, orthostatic hypotension, cardiac arrhythmia, agitation, insomnia or drowsiness, and depression.
  • Frequent delayed adverse effects or signs of excessive dosage include dyskinesia and tremor.
  • Mental disorders are more frequent in older patients and may include confusional state or depression with or without suicidal tendencies.
  • Later in treatment, fluctuation of effect during the day or reduction of effect may occur.
  • Administer with caution in mental disorders, cardiac disease, and gastroduodenal ulcer.
  • Do not administer simultaneously with MAOI antidepressants, antipsychotics, or reserpine.
  • Pregnancy: contraindicated.
  • Breast-feeding: contraindicated.

Source

MSF Essential drugs practical guidelines (January 2026)

This page reproduces the structured reference information for this batch while leaving out the Storage and Remarks sections.

Rate this guide

Be the first to rate this guide.